NCT01180868

Brief Summary

The purpose of this study is to determine the biodistribution of a new agent 1-L-(2 deoxy-2,-18fluoroarabinofuranosyl) cytosine non-invasively in healthy humans and to evaluate whether it can be used to image cancer, autoimmune disease, and inflammation

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

August 11, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 12, 2010

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
Last Updated

July 31, 2012

Status Verified

July 1, 2012

Enrollment Period

3.5 years

First QC Date

August 11, 2010

Last Update Submit

July 27, 2012

Conditions

Autoimmune DiseasesCancer

Keywords

imaging probecancerinflammatory tissueinflammatory diseases

Study Arms (3)

patients with cancer

patients with hematological malignancies and solid tumors

patients with autoimmune dosorders

patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.

healthy subjects

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with cancer, patients with autoimmune dosorders, and healthy subjects.

You may qualify if:

  • greater than 18 years of age
  • women of childbearing potential will undergo a pregnancy test free of charge
  • patients with hematological malignancies, solid tumors or autoimmune disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCLA

Los Angeles, California, 90095, United States

Location

MeSH Terms

Conditions

Autoimmune DiseasesNeoplasms

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

  • Christiaan Schiepers, M.D. Ph.D

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 11, 2010

First Posted

August 12, 2010

Study Start

May 1, 2008

Primary Completion

November 1, 2011

Last Updated

July 31, 2012

Record last verified: 2012-07

Locations

US(1)